EMA encourages companies to submit type I variations by end- November
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Self-collection devices designed for ease of use and safety
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
The project is a collaboration between IIT Delhi and AIIMS
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Subscribe To Our Newsletter & Stay Updated